



HEIDI A. DARE **SHAREHOLDER**

455 N. Cityfront Plaza Drive | Suite 3600
Chicago, IL 60611

P 312.321.4809
F 312.321.4299
hdare@brinksgilson.com

EDUCATION

J.D.,
Wayne State University Law School, 2002
M.S., Microbiology & Immunology
University of Michigan, 1988
B.A., Biology
Albion College, 1985

BAR ADMISSIONS

Illinois
U.S. Patent & Trademark Office

Heidi counsels clients in patent related matters including international patent portfolio management and due diligence analyses. Heidi's practice focuses on patent prosecution in technical areas of molecular biology, medical device and medical diagnostics. Heidi's prosecution experience includes preparing and prosecuting applications in technologies including RNA interference, recombinant nucleic acid and protein technologies, mutational analysis, antibody therapies, transgenic animals and plants, therapeutic vectors, stem cell therapies, and gene therapy.

Heidi counsels a diverse group of clients from corporate clients of all sizes, university clients and start-ups. Heidi has prosecuted over 1000 patent applications in the U.S. and worldwide.

Prior to joining the firm in 2002, Heidi's non-legal experience included research positions at Howard Hughes Medical Institute, University of Michigan and the Ohio State University.

EXPERIENCE | LEGAL

- **Brinks Gilson & Lione**, Chicago, Illinois
Shareholder, January 2011-Present
Associate, September 2002-December 2010
- **Brooks & Kushman, P.C.**, Southfield, Michigan
Law Clerk, May 2001-April 2002
Supported ongoing patent prosecution and litigation, including provisional applications and trademark litigation
- **University of Michigan, Office of the General Counsel**, Ann Arbor, Michigan
Law Clerk, 2000-2001
Researched issues for all areas of law, including patent law, copyrights, contracts, UCITA, Title IX, civil rights and property

PRACTICE GROUPS

Patent Prosecution
International Patent
Licensing

AREA OF FOCUS

Biosimilars

Biotechnology & Pharmaceutical

FORWARD THINKING

Alerts

- Federal Circuit Rules That Foreign Defendants Cannot Rely On 28 U.S.C. § 1400(b) To Challenge Venue, May 14, 2018
- *Versata v. SAP*: The Federal Circuit Can Review the CBM-Specific Threshold Question of Whether a Patent Qualifies as a "Covered Business Method Patent", July 17, 2015
- Update on CRISPR Patent Battle, January 10, 2017

HONORS

- Recommended Lawyer, *Legal 500*, 2017
- Leading Intellectual Property Lawyer, Leading Lawyers Network, 2012-2016

AFFILIATIONS

- American Bar Association
- Illinois Biotechnology Industry Organization (iBIO)

TECHNICAL BACKGROUND

- Biopharma

REPRESENTATIVE MATTERS

- **Authored Patents**
- U.S. 7,456,015: Tetracycline-Regulated Adeno-Associated Viral (AAV) Vectors for Gene Delivery to the Nervous System
- E.P. 1,799,826 B1: siRNA-Mediated Silencing of a-Synuclein
- **Authored Published Patent Applications**
- U.S. 2006/0118189: Flow Variation Valve Assembly
- U.S. 2007/0172462: siRNA-Mediated Gene Silencing of Synuclein
- U.S. 2007/0178071: Stem-Cell, Precursor Cell, or Target Cell-Based Treatment of Multiorgan Failure and Renal Dysfunction
- U.S. 2008/0027413: Blood Products from Mesenchymal Stem Cells
- U.S. 2008/0051721: Loop Tip Wire Guide
- U.S. 2008/0241112: Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
- U.S. 2008/0306465: Adjustable Length Catheter